http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
대한천식알레르기학회 알레르기비염 진료지침: 파트 2. 비약물치료의 업데이트
박상철 ( Sang Chul Park ),정수지 ( Soo Jie Chung ),최정희 ( Jeong-hee Choi ),이용주 ( Yong Ju Lee ),양현종 ( Hyeon-jong Yang ),박도양 ( Do-yang Park ),김동규 ( Dong-kyu Kim ),이일환 ( Il Hwan Lee ),김수환 ( Soo Whan Kim ),김도현 ( 대한천식알레르기학회 2023 Allergy Asthma & Respiratory Disease Vol.11 No.3
Allergic rhinitis is the most common chronic disease worldwide. Various upper airway symptoms lower quality of life, and due to the recurrent symptoms, multiple treatments are usually attempted rather than one definitive treatment. There are alternatives to medical (medication-based) and nonmedical treatments. A guideline is needed to understand allergic rhinitis and develop an appropriate treatment plan. We have developed guidelines for medical treatment based on previous reports. The current guidelines herein are associated with the “KAAACI Evidence-Based Guidelines for Allergic Rhinitis in Korea, Part 1: Update in pharmacotherapy” in which we aimed to provide evidence-based recommendations for the medical treatment of allergic rhinitis. Part 2 focuses on nonpharmacological management, including allergen-specific immunotherapy, subcutaneous or sublingual immunotherapy, nasal saline irrigation, environmental management strategies, companion animal management, and nasal turbinate surgery. The evidence to support the treatment efficacy, safety, and selection has been systematically reviewed. However, larger controlled studies are needed to elevate the level of evidence to select rational non-medical therapeutic options for patients with allergic rhinitis. (Allergy Asthma Respir Dis 2023;11:126-134)
대한천식알레르기학회 알레르기비염 진료지침: 파트 1. 약물치료의 업데이트
김민지 ( Minji Kim ),강성윤 ( Sung-yoon Kang ),양송이 ( Song-i Yang ),이일환 ( Il Hwan Lee ),류광희 ( Gwanghui Ryu ),김미애 ( Mi-ae Kim ),이상민 ( Sang Min Lee ),김현정 ( Hyun-jung Kim ),박도양 ( Do-yang Park ),이용주 ( Yong Ju Le 대한천식알레르기학회 2023 Allergy Asthma & Respiratory Disease Vol.11 No.3
The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines for AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and a systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes. (Allergy Asthma Respir Dis 2023;11:117-125)